The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksStandard Chartered Regulatory News (STAN)

Share Price Information for Standard Chartered (STAN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 681.40
Bid: 682.40
Ask: 682.80
Change: -1.40 (-0.21%)
Spread: 0.40 (0.059%)
Open: 691.00
High: 692.60
Low: 680.40
Prev. Close: 682.80
STAN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice to ADR Holders of 6.409% Preference Shares

27 Mar 2024 18:22

RNS Number : 5954I
Standard Chartered PLC
27 March 2024
 

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION (A) IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS, ANY STATE OF THE UNITED STATES AND THE DISTRICT OF COLUMBIA) (THE "UNITED STATES" OR THE "U.S.") OR TO ANY "U.S. PERSON" AS DEFINED IN REGULATION S UNDER THE UNITED STATES SECURITIES ACT OF 1933, AS AMENDED (THE "SECURITIES ACT"), OTHER THAN A "QUALIFIED INSTITUTIONAL BUYER" AS DEFINED IN RULE 144A UNDER THE SECURITIES ACT OR (B) IN OR INTO ANY OTHER JURISDICTION WHERE IT IS UNLAWFUL TO RELEASE, PUBLISH OR DISTRIBUTE THIS ANNOUNCEMENT.

27 March 2024

STANDARD CHARTERED PLC (a public limited company incorporated in England and Wales)

Announcement on Standard Chartered PLC's 6.409% non-cumulative redeemable preference shares (the "6.409% Preference Shares") represented by American Depositary Shares ("ADSs")

On 4 January 2023, Standard Chartered PLC (the "Company") announced that a proposal to transition the dividend rate for the 6.409% Preference Shares from a three month U.S. dollar LIBOR-based rate to a compounded SOFR-based rate had not been approved, and so would not be implemented.

On 19 June 2023, the Company announced that, as from the dividend period commencing 31 July 2023, the dividend rate payable on the 6.409% Preference Shares would be calculated by reference to the three month synthetic U.S. dollar LIBOR rate. The three month synthetic U.S. dollar LIBOR rate is calculated using three month CME Term SOFR plus the three month ISDA-recommended credit adjustment spread.

As the publication of three month synthetic U.S. dollar LIBOR is due to cease from 30 September 2024, the Company announces that it intends to commence proceedings in the High Court of Justice of England and Wales (the "Court") to seek a binding declaration on the use of an alternative benchmark rate to calculate the dividend rate payable on the 6.409% Preference Shares (the "Proceedings").

The Company currently anticipates commencing the Proceedings on or around 10 April 2024 and intends to request that the Proceedings be heard on an expedited basis, as the Company would like to provide investors with clarity and certainty on the dividend rate payable on the 6.409% Preference Shares following the cessation of the publication of three month synthetic U.S. dollar LIBOR.

It is for the Court to determine the most suitable alternative benchmark rate. To assist the Court in its consideration of this matter, the Company intends to present the Court with evidence about various alternative rates. The Company considers that three month CME Term SOFR plus the three month ISDA-recommended credit adjustment spread, as is currently used to calculate three month synthetic U.S. dollar LIBOR, would be the most suitable alternative rate. Accordingly, the Company intends to invite the Court to approve the use of this rate for the calculation of the dividend rate payable on the 6.409% Preference Shares. Term SOFR is a forward-looking rate that has been widely accepted as the alternative benchmark rate for U.S. dollar LIBOR in the U.S. and the U.K. The FCA has indicated that it considers synthetic U.S. dollar LIBOR to be a fair and reasonable approximation of U.S. dollar LIBOR's likely economic outcome.[1] The Company has been using synthetic U.S. dollar LIBOR to calculate the dividend rates payable on the 6.409% Preference Shares as from the dividend period commencing on 31 July 2023 and considers that it would be appropriate to continue to use the same methodology.

The Company is committed to identifying an alternative benchmark rate that fairly reflects the terms of the 6.409% Preference Shares.

JPMorgan Chase Bank, N.A. (the "Depositary") holds the role of depositary under the deposit agreement dated 8 December 2006 (as amended from time to time) establishing the ADSs representing the 6.409% Preference Shares (the "Deposit Agreement"). The 6.409% Preference Shares are currently held by a nominee of the Depositary, Guaranty Nominees Limited (the "Nominee").

However, neither the Depositary nor the Nominee (in those capacities) holds any economic interest in the 6.409% Preference Shares. Their role is essentially to hold the 6.409% Preference Shares for the benefit of, and to pass on payments and documents to, holders of the ADSs. Further, under the terms of the Deposit Agreement, neither the Depositary nor the Nominee is under any obligation to appear in, prosecute or defend any action, suit or other proceeding in respect of the 6.409% Preference Shares or the ADSs.

The Company has informed the Depositary of the Proceedings. Given that the Nominee is the sole registered holder of the 6.409% Preference Shares, it will be a necessary defendant in the Proceedings. However, in light of the above, the Company does not expect that either the Depositary or the Nominee will take an active role in the Proceedings. The Nominee will be named as the defendant as a procedural matter only.

The holders of the ADSs are not members of the Company and will not therefore be named by the Company as defendants in the Proceedings. However, recognising their economic interest in the 6.409% Preference Shares, the Company has provided the holders of the ADSs with additional information about the Proceedings which is available on the Company's website at https://www.sc.com/en/investors/credit-ratings-fixed-income/capital-securities-in-issue/. The Company invites the holders of the ADSs to notify it using the contact details provided below if they intend to participate in the Proceedings.

This announcement is released by the Company and contains information that qualified as inside information for the purposes of Article 7 of Regulation (EU) No 596/2014 as it forms part of the domestic law of the U.K. by virtue of the EUWA ("UK MAR"), encompassing information relating to the 6.409% Preference Shares described above.

The Company does not, at this stage, intend to comment further on the Proceedings.

 

Debt Investor RelationsEmail: Investor.Relations@sc.com

Tel: +44 207 885 8888

 

Debt Capital Markets Email: Primary.Debt@sc.com / SCBCapitalMarketsNotice@sc.com

Tel: +44 207 885 8888

 

Group Media RelationsShaun GambleEmail: shaun.gamble@sc.com Tel: +44 7766 443 662


[1] Paragraph 3.66 of the FCA's Consultation Paper CP22/21: "Consultation on 'synthetic' US dollar LIBOR and feedback to CP22/11" dated November 2022. 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
MSCPPUUPWUPCGRM
Date   Source Headline
26th Apr 20245:30 pmRNSTransaction in Own Shares
26th Apr 202410:17 amRNSOverseas Regulatory Announcement
25th Apr 20245:50 pmRNSTransaction in Own Shares
24th Apr 20246:25 pmRNSPublication of a Prospectus
24th Apr 20245:19 pmRNSTransaction in Own Shares
23rd Apr 20245:50 pmRNSTransaction in Own Shares
22nd Apr 20245:40 pmRNSTransaction in Own Shares
19th Apr 20245:35 pmRNSTransaction in Own Shares
18th Apr 20245:35 pmRNSTransaction in Own Shares
17th Apr 20245:35 pmRNSTransaction in Own Shares
16th Apr 20245:35 pmRNSTransaction in Own Shares
15th Apr 20246:05 pmRNSTransaction in Own Shares
12th Apr 20244:54 pmRNSTransaction in Own Shares
12th Apr 20242:05 pmRNSNotice to ADR Holders of 6.409% Preference Shares
11th Apr 20245:45 pmRNSTransaction in Own Shares
10th Apr 20245:30 pmRNSTransaction in Own Shares
9th Apr 20246:05 pmRNSTransaction in Own Shares
8th Apr 20245:16 pmRNSTransaction in Own Shares
8th Apr 202411:32 amRNSNotice of AGM 2024 and Notice of Class Meeting
5th Apr 202410:30 amRNSOverseas Regulatory Announcement
4th Apr 20245:30 pmRNSTransaction in Own Shares
3rd Apr 20245:13 pmRNSTransaction in Own Shares
2nd Apr 20245:45 pmRNSTransaction in Own Shares
2nd Apr 202410:54 amRNSTotal Voting Rights
2nd Apr 20249:30 amRNSChanges to presentation of financial information
28th Mar 20246:00 pmRNSTransaction in Own Shares
27th Mar 20246:22 pmRNSNotice to ADR Holders of 6.409% Preference Shares
27th Mar 20245:39 pmRNSTransaction in Own Shares
26th Mar 20245:35 pmRNSTransaction in Own Shares
26th Mar 20244:36 pmRNSDirector/PDMR Shareholding
25th Mar 20245:43 pmRNSTransaction in Own Shares
22nd Mar 20245:35 pmRNSTransaction in Own Shares
21st Mar 20245:55 pmRNSTransaction in Own Shares
20th Mar 20245:30 pmRNSTransaction in Own Shares
20th Mar 20243:08 pmRNSDirector/PDMR Shareholding
19th Mar 20246:05 pmRNSTransaction in Own Shares
19th Mar 20245:45 pmRNSPublication of Final Terms
18th Mar 20245:51 pmRNSTransaction in Own Shares
15th Mar 20245:53 pmRNSTransaction in Own Shares
15th Mar 20244:45 pmRNSHolding(s) in Company
15th Mar 20244:30 pmRNSDirector/PDMR Shareholding
15th Mar 20243:35 pmRNSDirector/PDMR Shareholding
15th Mar 202410:30 amRNSHolding(s) in Company
14th Mar 20246:05 pmRNSTransaction in Own Shares
14th Mar 20242:03 pmRNSTotal Voting Rights
14th Mar 202411:05 amRNSDirector/PDMR Shareholding
13th Mar 20246:02 pmRNSTransaction in Own Shares
13th Mar 20246:00 pmRNSPublication of Supplementary Prospectus
13th Mar 202411:26 amRNSOverseas Regulatory Announcement – Grant of awards
13th Mar 202410:45 amRNSDirector/PDMR Shareholding

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.